Intra-Cellular Therapies to Present at the 2021 Cantor Virtual Global Healthcare Conference
September 22, 2021 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Announces Publications Highlighting Beneficial Effects of Phosphodiesterase Type I Inhibition with Lenrispodun (ITI-214) on Cardiovascular Function in Patients with Heart Failure and in Models of Accelerated Aging
September 20, 2021 07:30 ET
|
Intra-Cellular Therapies Inc.
Results of Study ITI-214-104 show that lenrispodun, in a Phase 1/2a Study, is well tolerated and acts as an inodilator in patients with heart failure without inducing abnormal heart rhythms...
Intra-Cellular Therapies to Present at the Canaccord Genuity 41st Annual Growth Conference
August 10, 2021 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 09, 2021 07:30 ET
|
Intra-Cellular Therapies Inc.
CAPLYTA supplemental new drug applications (sNDAs) for the treatment of bipolar depression are under review by the FDA, with a PDUFA target action date of December 17, 2021. Second quarter CAPLYTA...
Intra-Cellular Therapies to Host Second Quarter 2021 Financial Results Conference Call and Webcast
August 02, 2021 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
CAPLYTA® (lumateperone) Schizophrenia Safety and Tolerability Profile Published in the Journal, International Clinical Psychopharmacology
June 07, 2021 08:00 ET
|
Intra-Cellular Therapies Inc.
Pooled analysis of 3 randomized, double-blind, pacebo-cotrolled trials supports the safety and the distinct and favorable tolerability profile of lumateperone 42 mg Mean change from baseline in...
Intra-Cellular Therapies to Present at Two Upcoming Investor Conferences
May 26, 2021 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 10, 2021 07:30 ET
|
Intra-Cellular Therapies Inc.
CAPLYTA supplemental new drug applications (sNDAs) for the treatment of bipolar depression in adults as both monotherapy and adjunctive treatment with lithium or valproate have been accepted for...
Intra-Cellular Therapies to Present at Two Upcoming Investor Conferences
May 05, 2021 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, May 05, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies to Host First Quarter 2021 Financial Results Conference Call and Webcast
May 04, 2021 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, May 04, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...